[1] Le M H, Yeo Y H, Li X, et al. 2019 global NAFLD prevalence: A systematic review and Meta-analysis. Clin Gastroenterol Hepatol, 2022, 20(12): 2809-17,e28.
[2] Li J, Zou B, Yeo Y H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and Meta-analysis. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.
[3] Sanyal A J, van Natta M L, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med, 2021, 385(17): 1559-1569.
[4] Adams L A, Aantee Q M, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases . Gut, 2017, 66(6): 1138-1153.
[5] Kanwal F, Kramer J R, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease . Hepatology, 2020, 71(3): 808-819.
[6] Zhou Y Y, Zhou X D, Wu S J, et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol, 2018, 30(6): 631-636.
[7] Kanwal F, Shubrook J H, Adams L A, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology, 2021, 161(5): 1657-1669.
[8] Unalp-Arida A, Ruhl C E. Liver fibrosis scores predict liver disease mortality in the United States population . Hepatology, 2017, 66(1): 84-95.
[9] Siddiqui M S, Vuppalanchi R, van Natta M L, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019, 17(1): 156-163,e2.
[10] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD) . Endocr Pract, 2022, 28(5): 528-562.
[11] Chalmers J, Wilkes E, Harris R, et al. The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community . Frontline Gastroenterol, 2020, 11(2): 86-92.
[12] Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease . J Hepatol, 2019, 71(2): 371-378.
[13] Mantovani A, Byrne C D, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A Meta-analysis. Diabetes Care, 2018, 41(2): 372-382.
[14] Bonnet F, Gastaldelli A, Pihan-Le Bars F, et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens, 2017, 35(3): 493-500.
[15] Lau K, Lorbeer R, Haring R, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens, 2010, 28(9): 1829-1835.
[16] Lazarus J V, Mark H E, Aantee Q M, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol, 2022, 19(1): 60-78. |
